<?xml version='1.0' encoding='utf-8'?>
<document id="30167757"><sentence text="Voriconazole greatly increases the exposure to oral buprenorphine."><entity charOffset="0-12" id="DDI-PubMed.30167757.s1.e0" text="Voriconazole" /><entity charOffset="52-65" id="DDI-PubMed.30167757.s1.e1" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.30167757.s1.e0" e2="DDI-PubMed.30167757.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30167757.s1.e0" e2="DDI-PubMed.30167757.s1.e1" /></sentence><sentence text="Buprenorphine has low oral bioavailability"><entity charOffset="0-13" id="DDI-PubMed.30167757.s2.e0" text="Buprenorphine" /></sentence><sentence text=" Regardless of sublingual administration, a notable part of buprenorphine is exposed to extensive first-pass metabolism by the cytochrome P450 (CYP) 3A4"><entity charOffset="60-73" id="DDI-PubMed.30167757.s3.e0" text="buprenorphine" /></sentence><sentence text=" As drug interaction studies with buprenorphine are limited, we wanted to investigate the effect of voriconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics and pharmacodynamics of oral buprenorphine"><entity charOffset="34-47" id="DDI-PubMed.30167757.s4.e0" text="buprenorphine" /><entity charOffset="100-112" id="DDI-PubMed.30167757.s4.e1" text="voriconazole" /><entity charOffset="194-207" id="DDI-PubMed.30167757.s4.e2" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.30167757.s4.e0" e2="DDI-PubMed.30167757.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30167757.s4.e0" e2="DDI-PubMed.30167757.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30167757.s4.e0" e2="DDI-PubMed.30167757.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30167757.s4.e1" e2="DDI-PubMed.30167757.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30167757.s4.e1" e2="DDI-PubMed.30167757.s4.e2" /></sentence><sentence text="" /><sentence text="Twelve healthy volunteers were given either placebo or voriconazole (orally, 400 mg twice on day 1 and 200 mg twice on days 2-5) for 5 days in a randomized, cross-over study"><entity charOffset="55-67" id="DDI-PubMed.30167757.s6.e0" text="voriconazole" /></sentence><sentence text=" On day 5, they ingested 0" /><sentence text="2 mg (3" /><sentence text="6 mg during placebo phase) oral buprenorphine"><entity charOffset="32-45" id="DDI-PubMed.30167757.s9.e0" text="buprenorphine" /></sentence><sentence text=" We measured plasma and urine concentrations of buprenorphine and norbuprenorphine and monitored their pharmacological effects"><entity charOffset="48-61" id="DDI-PubMed.30167757.s10.e0" text="buprenorphine" /><entity charOffset="66-82" id="DDI-PubMed.30167757.s10.e1" text="norbuprenorphine" /><pair ddi="false" e1="DDI-PubMed.30167757.s10.e0" e2="DDI-PubMed.30167757.s10.e0" /><pair ddi="false" e1="DDI-PubMed.30167757.s10.e0" e2="DDI-PubMed.30167757.s10.e1" /></sentence><sentence text=" Pharmacokinetic parameters were normalized for a buprenorphine dose of 1"><entity charOffset="50-63" id="DDI-PubMed.30167757.s11.e0" text="buprenorphine" /></sentence><sentence text="0 mg" /><sentence text="" /><sentence text="Voriconazole greatly increased the mean area under the plasma concentration-time curve (AUC0-18) of buprenorphine (4"><entity charOffset="0-12" id="DDI-PubMed.30167757.s14.e0" text="Voriconazole" /><entity charOffset="100-113" id="DDI-PubMed.30167757.s14.e1" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.30167757.s14.e0" e2="DDI-PubMed.30167757.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30167757.s14.e0" e2="DDI-PubMed.30167757.s14.e1" /></sentence><sentence text="3-fold, P &lt; 0" /><sentence text="001), its peak concentration (Cmax) (3" /><sentence text="9-fold), half-life (P &lt; 0" /><sentence text="05), and excretion into urine (Ae; P &lt; 0" /><sentence text="001)" /><sentence text=" Voriconazole also markedly enhanced the Cmax (P &lt; 0"><entity charOffset="1-13" id="DDI-PubMed.30167757.s20.e0" text="Voriconazole" /></sentence><sentence text="001), AUC0-18 (P &lt; 0" /><sentence text="001), and Ae (P &lt; 0" /><sentence text="05) of unconjugated norbuprenorphine but decreased its renal clearance (P &lt; 0"><entity charOffset="20-36" id="DDI-PubMed.30167757.s23.e0" text="norbuprenorphine" /></sentence><sentence text="001)" /><sentence text=" Mild dizziness and nausea occurred during both study phases" /><sentence text="" /><sentence text="Voriconazole greatly increases exposure to oral buprenorphine, mainly by inhibiting intestinal and liver CYP3A4"><entity charOffset="0-12" id="DDI-PubMed.30167757.s27.e0" text="Voriconazole" /><entity charOffset="48-61" id="DDI-PubMed.30167757.s27.e1" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.30167757.s27.e0" e2="DDI-PubMed.30167757.s27.e0" /><pair ddi="false" e1="DDI-PubMed.30167757.s27.e0" e2="DDI-PubMed.30167757.s27.e1" /></sentence><sentence text=" Effect on some transporters may explain elevated norbuprenorphine concentrations"><entity charOffset="50-66" id="DDI-PubMed.30167757.s28.e0" text="norbuprenorphine" /></sentence><sentence text=" Although oral buprenorphine is not commonly used, this interaction may become relevant in patients receiving sublingual buprenorphine together with voriconazole or other CYP3A4 or transporter inhibitors"><entity charOffset="15-28" id="DDI-PubMed.30167757.s29.e0" text="buprenorphine" /><entity charOffset="121-134" id="DDI-PubMed.30167757.s29.e1" text="buprenorphine" /><entity charOffset="149-161" id="DDI-PubMed.30167757.s29.e2" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.30167757.s29.e0" e2="DDI-PubMed.30167757.s29.e0" /><pair ddi="false" e1="DDI-PubMed.30167757.s29.e0" e2="DDI-PubMed.30167757.s29.e1" /><pair ddi="false" e1="DDI-PubMed.30167757.s29.e0" e2="DDI-PubMed.30167757.s29.e2" /><pair ddi="false" e1="DDI-PubMed.30167757.s29.e1" e2="DDI-PubMed.30167757.s29.e1" /><pair ddi="false" e1="DDI-PubMed.30167757.s29.e1" e2="DDI-PubMed.30167757.s29.e2" /></sentence><sentence text="" /></document>